Covid-19 Pandemic
 Here’s the latest news: Growing Russian outbreak spreads to MongoliaCoronavirus spurs spike in children’s blood disorder‘Unacceptable’ for U.S. to get Sanofi vaccine first, France says Will the vaccine race stop at the border? As the U.S. government rushes to bring a coronavirus vaccine to more than 300 million Americans in record time, it has given money to drugmakers with promising candidates: Johnson & Johnson, Moderna and Sanofi. One of these things is not like the others. Unlike American bellwether J&J and Cambridge, Massachusetts-based biotech Moderna, Sanofi’s headquarters sit in Paris. The company has long been a gem in the crown of the French economy. But now, should Sanofi be successful in delivering a vaccine against the novel coronavirus, the U.S. will likely be first in line to get it. “The U.S. government has the right to the largest pre-order because it’s invested in taking the risk,” Chief Executive Officer Paul Hudson told Bloomberg reporters during a video interview from his home in Paris. The U.S., which expanded a vaccine partnership with Sanofi in February, expects “that if we’ve helped you manufacture the doses at risk, we expect to get the doses first.” The European Union has been less coordinated, Hudson noted, though he’s encouraged by recent efforts led by France and Germany.  Photographer: Ulrich Baumgarten/via Gerry Images The debate over a coronavirus vaccine is shifting from biology to borders. Public-health advocates are concerned about the potential for vaccine nationalism, where wealthier countries aiding industry research, development and production could monopolize the global supply of forthcoming shots. While funding from the Biomedical Advanced Research and Development Authority means the U.S. likely will get Sanofi’s vaccine before the rest of the world, the country may only be days or weeks ahead of everyone else, Hudson said.Still, no one company has the production capabilities to meet global demand. That means more than one vaccine needs to prove effective against the virus, Hudson said. Whether universal access is a feasible goal or an impossible dream remains to be seen.—Riley Griffin Listen up Latest Podcast: The Scary Rise of Covid Toe Doctors around the world are learning the coronavirus attacks more than the lungs. Jason Gale reports on how much more we have yet to learn about what the virus does to the body.  What you should read Remdesivir Shows Rare Pandemic Foresight How Gilead Sciences prepared for the first good news of the outbreak. The U.K.’s Restart Plan Is Stalled Trying to reboot the economy while extending a stay-at-home pay program. Investors Sound Alarm on Stock Prices Trump tries to bat down billionaire investors with a tweet. Hard-to-Trace Flare-Ups Plague Asian Recovery Stealthy virus makes eradication near-impossible, experts say. Tokyo Stays Under Emergency as Japan Eases Status in Tokyo, Osaka will be reviewed in a week, PM Abe says. Know someone else who would like this newsletter? Have them sign up here. Have any questions, concerns, or news tips on Covid-19 news? Get in touch or help us cover the story. Like this newsletter? Subscribe for unlimited access to trusted, data-based journalism in 120 countries around the world and gain expert analysis from exclusive daily newsletters, The Bloomberg Open and The Bloomberg Close. Follow Us Get the newsletter You received this message because you are subscribed to Bloomberg’s Coronavirus Daily newsletter. Unsubscribe | Bloomberg.com | Contact Us Bloomberg L.P. 731 Lexington, New York, NY, 10022 |
PreviousCovid-19 Pandemic